Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

A new grant from the UK Academy of Medical Sciences will allow clinicians and scientists from Oxford, Sri Lanka and Thailand to establish new ties to support research into β thalassaemia and benefit those most affected.

Prof Doug Higgs and Dr Sachith Mettananda
Prof Doug Higgs and Dr Sachith Mettananda

β-Thalassaemia is a type of anaemia where a faulty gene leads to misproduction of haemoglobin in red blood cells. No cure is available, except for rare cases where a suitable bone marrow donor can be found. The disease predominantly affects the impoverished communities in the developing world, particularly South and South East Asia.

To develop and support research for new therapies in the areas most affected Dr Sachith Mettananda, a recent graduate from the MRC WIMM and now based at the University of Kelaniya in Sri Lanka, and Prof Doug Higgs (MRC Molecular Haematology Unit, Radcliffe Department of Medicine) successfully applied for a Global Challenges Research Fund Networking Grant, awarded by the UK Academy of Medical Sciences. The researchers plan to use the £25,000 award to fund a series of networking events across the UK, Sri Lanka and Thailand. These will strengthen the existing ties between Sri Lanka and the UK but also establishing a new regional network of researchers and clinicians working on this condition. The award will also help support pilot research in Sri Lanka, in order to build capacity to perform independent genetic therapeutic-based research in this country, with the ultimate aim of providing cutting edge therapies to local patients.

This award is the most recent step in a long history connecting the MRC WIMM to progress in thalassaemia research. Prof Sir David Weatherall, who founded our Institute in 1989, was the first to describe thalassaemia outside the Mediterranean, and over the years our researchers have established the molecular basis of this disease, as well as improved diagnosis and treatment options.

Similar stories

Mechanism behind repair of cancer-inducing mutations discovered

New Nature paper uncovers the precise mechanism behind how the BRCA1 protein detects and engages with DNA breaks in the genome, helping to prevent the development of breast and ovarian cancers.

DNA breakthrough could help identify why some people are more affected by Covid-19

Scientists from the MRC Weatherall Institute of Molecular Medicine have developed a method that allows them to see, with far greater accuracy, how DNA forms large scale structures within a cell nucleus.

New clinical trial for patients affected by blood cancer

Radcliffe Department of Medicine's Professor Adam Mead is leading PROMise, a new clinical trial offering a novel treatment option for patients with a type of blood cancer called myelofibrosis.

Immune cells imperfect at distinguishing friend from foe

When it comes to distinguishing a healthy cell from an infected one that needs to be destroyed, the immune system’s killer T cells sometimes make mistakes. This discovery, described today in the journal eLife, upends a long-held belief among scientists that T cells were nearly perfect at discriminating friend from foe. The results may point to new ways to treat autoimmune diseases that cause the immune system to attack the body, or lead to improvements in cutting-edge cancer treatments.

Professor Graham Ogg elected Academy of Medical Sciences Fellow

Fellows are selected for their exceptional contributions to the advancement of medical science through innovative research discoveries and translating scientific developments into benefits for patients and the wider society.